Core Viewpoint - Investors who suffered losses from the stock of Doctor Glasses (stock code: 300622) can seek compensation following the China Securities Regulatory Commission's (CSRC) decision regarding market manipulation by an individual named Yu [1][2][3] Group 1: Case Background - The CSRC issued an administrative penalty decision on January 9, 2026, revealing that Yu manipulated the stock market by controlling 67 accounts to trade Doctor Glasses from June 25, 2019, to August 16, 2024 [1][4] - Yu's manipulation involved using concentrated capital and stock advantages to influence the trading price and volume of Doctor Glasses [1][4] - The illegal gains from Yu's actions were calculated to be approximately 510.89 million yuan [1][4] Group 2: Legal Framework and Compensation Process - According to Article 55 of the Securities Law, manipulating the stock market is prohibited, and those causing losses to investors must bear compensation responsibilities [2][4] - The law firm is currently assisting investors in filing claims, specifically for those who traded Doctor Glasses stock between June 25, 2019, and August 30, 2024 [2][4] - Investors seeking compensation must provide specific documentation, including securities account information and transaction statements from January 1, 2019, to December 31, 2024 [2][4]

Core Viewpoint - Zhao Yeqing and associates manipulated the stock of Jincheng Pharmaceutical, resulting in significant financial losses and subsequent regulatory penalties, leading to Zhao's resignation as chairman and director of the company [1][3][4]. Group 1: Regulatory Actions and Penalties - The China Securities Regulatory Commission (CSRC) found that from August 18, 2017, to February 10, 2020, Zhao Yeqing, along with Wang Zhen and Liu Feng, controlled 104 securities accounts to trade Jincheng Pharmaceutical stock, incurring losses exceeding 7 million yuan [2][3]. - The accounts engaged in frequent trading over 595 trading days, with 502 days of active trading, resulting in a total buy amount of 2.134 billion yuan and a sell amount of approximately 1.870 billion yuan [2]. - The CSRC imposed a total fine of 3 million yuan on Zhao Yeqing, Wang Zhen, and Liu Feng, with Zhao personally liable for 1.5 million yuan, and instituted market bans of 4 years for Zhao and 3 years for Wang [3]. Group 2: Company Impact and Financial Performance - Following the regulatory actions, Zhao Yeqing submitted his resignation from all positions within Jincheng Pharmaceutical, effective immediately, while the company stated that the penalties only pertained to Zhao personally and did not affect the company's operations [4]. - As of the announcement date, Zhao held approximately 2.88% of the company's total shares, and the company is in the process of electing a new chairman [4]. - Jincheng Pharmaceutical, listed on the Shenzhen Stock Exchange since June 2011, reported a revenue of 1.932 billion yuan for the first three quarters of 2025, a year-on-year decline of 23.19%, with a net profit of 31.58 million yuan, down 79.1% [4]. - The company experienced a net loss of 11.81 million yuan in the third quarter, a significant decline of 157.7% year-on-year [4]. Group 3: Product Development - Jincheng Pharmaceutical has made progress in product development, recently obtaining registration certificates for "Dihydrosulfonyladenosine enteric-coated tablets" and "medical gynecological gel," aiming to diversify its product line to address operational challenges [5].